On June 2, Ali Health rose 3.21% in regular trading, trading at HK$3.87/share, with trading volume of HK$182 million, rebounding after consecutive post-earnings declines.

On the news front, the company recently signed a strategic cooperation agreement with men's health leader Menarini, jointly releasing the China Men's Health and Medication Trends Insight Report. The two parties will collaborate through a model combining original drug launches, scientific medication guidance, and digital health management to drive business synergies.

Simultaneously, the broader Internet and Direct Marketing Retail sector rallied strongly, with BABA-W up 5.29%, Meituan-W up 8.37%, JD-SW up 4.0%, and PA Good Doctor up 4.06%. The sector-wide linkage effect provided rebound momentum for Ali Health, which had been under sustained pressure after multiple investment banks collectively cut target prices following weaker-than-expected FY26 results, where second-half revenue growth of 7.6% significantly missed the market consensus of 13.8%.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)